LX12001

LX12001 is a potent and selective small molecule inhibitor of arachidonate 12-lipoxygenase (ALOX12), an enzyme that catalyzes the conversion of arachidonic acid into 12-hydroxyeicosatetraenoic acid (12-HETE). Developed by Loxagen, LX12001 is designed to address the underlying inflammatory and oxidative stress pathways in Type 1 Diabetes (T1D) and Pancreatic Ductal Adenocarcinoma (PDAC). In T1D, ALOX12 inhibition aims to protect pancreatic beta cells from cytokine-induced apoptosis and oxidative damage, thereby preserving endogenous insulin production. In the context of PDAC, the drug targets the ALOX12/12-HETE axis to modulate the tumor microenvironment and inhibit cancer cell survival and metastasis. LX12001 is currently in the IND-enabling phase of development.